Dapagliflozin - AstraZeneca

Drug Profile

Dapagliflozin - AstraZeneca

Alternative Names: anda Tang; Andatang; BMS-512148; Dapagliflozin propanediol; Farxiga; Forxiga; Oxra

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; AstraZeneca KK; Bristol-Myers Squibb; Ono Pharmaceutical; University Medical Center Groningen; Uppsala University
  • Class Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucosides; Pyrans; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Preregistration Type 1 diabetes mellitus
  • Phase III Chronic heart failure; Renal failure
  • Phase II Kidney disorders; Obesity

Most Recent Events

  • 31 Jul 2018 AstraZeneca plans the DS Navigation phase III trial for Type II diabetes mellitus in China and Vietnam , (NCT03608358)
  • 25 Jun 2018 Efficacy and adverse events data from the phase III DEPICT-1 trial in Type 1 diabetes mellitus released by AstraZeneca
  • 25 Jun 2018 Efficacy and adverse events data from the phase III DEPICT-2 trial in Type 1 diabetes mellitus released by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top